AZNAstraZenecaRunning, no new patients
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Hepatocellular Carcinoma (HCC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 58 (final count)
- Started
- Feb 13, 2024
- Main results expected
- Jun 30, 2026
- Fully finished
- May 27, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: From Day 1 until date of progressive disease or death [Approximately 3 years]
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06040099 · record last updated 2026-09-21 · checked 2026-11-09 15:47 UTC